User:JG8828/PKM2/Bibliography

Outline of proposed changes
Information about PKM2's role in metabolism from the papers by Puckett et al. (2021) and Zhang et al. (2019) can be used to further refine existing statements about PKM2 with regards to its role within metabolism. For instance, there is significant focus on the tetrameric:dimeric ratio of PKM2, and how ratio imbalances lead to the promotion of cancerous cells. However, there is a lack of commentary on the article about potential avenues for which targeting PKM2 can be used as a therapeutic approach. Puckett describes this under "4.3.1 PKM2 Activators", making references to how small molecules such as TEPP-46 can be used to increase levels of tetrameric PKM2 and ultimately, reduce tumor burden. Discussion from Zahra et al. (2020) can be used to build on this, as it was discussed that activators like quinolone sulfonamide promotes the conversion of dimeric PKM2 to its tetrameric form, a shift that reduces the glycolytic intermediates used by cancerous cells.

Furthermore, there is no information about the discovery of PKM2 by Dr. Otto Heinrich Warburg in Germany. Zhang et al. (2019) did provide a brief narrative of how this came to be and what the Warburg effect, named after the discoverer, entails in a physiological setting. With this, I'd like to also update the page by providing historical context for its discovery and its implications. Additionally, information from the paper by Wong et al. (2015) can further this narrative about the Warburg effect, as the team discussed experiments from other researchers that look at how molecular inhibitors have been used to mimic PKM2 knockdown, which reduces the Warburg effect.

Lastly, there are also slight issues with sentence structure and grammar that I'd like to correct in my revision of the PKM2 article.